More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair.
According to survey results presented at ASHG, most genetics experts support somatic and germline gene editing, though few favor trait enhancement.
There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.
In a survey of 132 oncologists, Medscape tracked how they are using next-generation sequencing and what they think of its clinical utility.
There is significant interest in technologies that provide long-range genomic information, but only among a subset of users.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
Researchers examined the patient-physician relationship after sharing personal genetic testing results and found that patients may have certain expectations.
A Vanderbilt University survey revealed most clinicians don't need convincing PGx testing is useful, but they don't agree which provider is responsible for the next step.
Around 70 percent of cancer compounds and 40 percent of compounds for all indications are being developed with biomarker data.
Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.
360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.
The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.
In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.
Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.